No relevant differences were found in DR3 expression by CD8+ T lymphocytes (active disease 19.0 % ± 5.8; inactive sarcoidosis 17.0 % ± 4.7; controls: 14.6 % ± 5.8, of CD8+ T cells; p: not significant), whereas AMs from patients with active sarcoidosis were marked out by the highest DR3 expression (36.0 % ± 11.7) as compared to inactive sarcoidosis (12.2 % ± 7.1 of AMs; p < 0.01 vs active disease), and to controls (11.3 % ± 3.8 of AMs; p < 0.01 vs active disease; ANOVA p < 0.01) (Fig. 1b). This evidence concerns the gene TNFRSF25 and sarcoidosis.